Wenzel Spine, Inc., a medical device company focused on providing less invasive, stand-alone alternatives to traditional spinal fusion, today announced that it has successfully surpassed the 26,000th implantation of its Stand-Alone VariLift Expandable Interbody Fusion Device.
The VariLift System provides a minimally invasive, stand-alone solution for interbody fusion procedures. The VariLift technology is intended for use in single or two contiguous levels in the lumbar spine (L2-S1) for the treatment of degenerative disc disease and related instability. VariLift is cleared by the Federal Drug Administration (FDA) for Posterior, Transforaminal, and Anterior Lumbar Interbody Fusion applications and without supplemental fixation. Wenzel Spine's VariLift System including VariLift-C, a cervical device design and application, received CE Mark approval in November 2010 and is used across Europe.
"We are pleased to reach this significant milestone," said Chad Neely, Chief Executive Officer of Wenzel Spine, Inc. "VariLift has experienced tremendous success worldwide and we look forward to achieving the same success in the US as we begin our full market release with the 2011 launch of VariLift."
VariLift is currently the only FDA cleared stand-alone interbody fusion device that expands in-situ, providing a proven, minimally invasive alternative to traditional spinal fusion.
"VariLift is an exciting option for spine surgeons performing lumbar fusion surgery as it creates immediate stability and fixation by expanding in-situ once it's properly positioned," says Daniel Peterson, M.D., former Chief of Staff at Brackenridge Hospital in Austin, TX and current clinical adjunct professor of Biomedical Engineering at the University of Texas. "VariLift's patented design offers patients a minimally invasive alternative to traditional lumbar fusion surgery."
New study reveals optimal drug sequencing for postmenopausal osteoporosis treatment